Immunotherapy with allergens

JAMA

Volumn 278, Issue 22, 1997, Pages 1881-1887

  Weber, Richard W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; INTERLEUKIN 4; PLACEBO; POLLEN ANTIGEN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANTIBODY RESPONSE; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATORY CELL; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0031454796     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1881     Document Type: Review

References (91)

1. Noon L. Prophylactic inoculation against hayfever. Lancet. 1911;1:1572-1573.
2. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;2:814-817.
3. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Mud. 1965;273:675-679.
4. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma. Lancet. 1954;1:1055-1057.
5. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollinosis. JAMA. 1967;201:915-917.
6. Pence HL, Mitchell DQ, Greely RL, Udegraff BR, Selfridge HA. Immunotherapy for mountain cedar pollinosis: a double-blind controlled study. J Allergy Clin Immunol. 1976;58:39-50.
7. Aas K. Hyposensitization in house dust allergy asthma: a double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 1971;60:264-268.
8. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2:912-915.
9. Bousquet J, Calvayrac P, Guérin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, I: in vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985;76:734-744.
10. Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. J Allergy Clin Immunol. 1984;74:230-239.
11. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988;82:1055-1068.
12. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts, V: effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87:955-964.
13. Østerballe O. Immunotherapy with grass pollen major allergens. Allergy. 1982;37:379-388.
14. Frostad AB, Grimmer Ø, Sandvik L, Moxnes A, Aas K. Clinical effects of hyposensitization using a purified allergen preparation from timothy pollen as compared to crude aqueous extracts from timothy pollen and a four-grass mixture respectively. Clin Allergy. 1983;13:337-357.
15. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol. 1989;84:197-205.
16. Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria. Am J Respir Crit Care Med. 1995;152:461-466.
17. Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy, V: clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy. 1986;41:507-519.
18. Horst M, Hejjaoui A, Horst V, Michel F-B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85:460-472.
19. Van Bever HP, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy. 1989;19:399-404.
20. Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol. 1991;87:721-728.
21. Rogers BL, Bond JF, Craig SJ, et al. Potential therapeutic recombinant proteins comprised of peptides containing recombined T cell epitopes. Mol Immunol. 1994;31:955-966.
22. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Enql J Med. 1978;299:157-161.
23. Strom GB, Boswell RN, Jacobs RL. In vivo and in vitro comparison of fire ant venom and fire ant whole body extract. J Allergy Clin Immunol. 1983;72:46-53.
24. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? Am J Respir Crit Care Med. 1995;151:969-974.
25. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334:501-506.
26. Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med. 1996;334:531-532.
27. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997;336:324-331.
28. Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr. 1984;104:664-668.
29. Graft DF. When to start, when to stop, and what to measure in venom immunotherapy: issues in allergy grand seminar, AAAI annual meeting 1990. J Allergy Clin Immunol. 1991;88:409-113.
30. Oppenheimer JJ, Nelson HA, Bock SA, Christensen F, Leung DYM. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256-262.
31. Loveless MH. Immunologic studies m pollinosis, IV: the relationship between thermostable antibody in the circulation and clinical immunity. J Immunol. 1943;47:165-180.
32. Alexander HL, Johnson MC, Bukantz SC. Studies on correlation between symptoms of ragweed hay-fever and titer of thermostable antibody. J Allergy. 1948;19:1-8.
33. Zeiss CR, Metzger WJ, Levitz D. Quantitative relationships between IgE antibody and blocking antibodies specific for antigen E in patients given immunotherapy with ragweed antigen E. Clin Exp Immunol. 1977;28:250-255.
34. Gleich GJ, Zimmerman EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982;70:261-271.
35. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NFJr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol. 1984;73: 94-104.
36. Djurup R, Østerballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Allergy. 1984;39:433-441.
37. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 1980; 302:1213-1219.
38. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol. 1987;79:591-598.
39. Hsieh K-H. Altered interleukin-2 (IL-2) production and responsiveness after hyposensitization to house dust. J Allergy Clin Immunol. 1985;76:188-194.
40. Hsieh K-H. Decreased production of interleukin-2 receptors after immunotherapy to house dust. J Clin Immunol. 1988;8:171-177.
41. Bonno M, Fujisawa T, Iguchi K, et al. Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy. J Allergy Clin Immunol. 1996;97:680-688.
42. Hsieh K-H, Ng C-K. Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. J Allergy Clin Immunol. 1993;91:650-657.
43. Kuna P, Alam R, Kuzminska B, Roznieki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma. J Allergy Clin Immunol. 1989;83:816-824.
44. Jung CM, Prinz JC, Rieber EP, Ring J. A reduction in allergen-induced Fc∈R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol. 1995;95:77-87.
45. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy. 1991;21:115-119.
46. Rak S, Björnson A, Håkanson L, Sorenson S, Venge V. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol. 1991;88:878-888.
47. Iliopoulos O, Proud D, Adkinson NF Jr, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen. J Allergy Clin Immunol. 1991;87:855-866.
48. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-g. J Allergy Clin Immunol. 1996;97:1356-1365.
49. Colmes A, Rackemann FM. Further observations on the changes in skin tests following specific pollen therapy. J Allergy. 1933;4:473-480.
50. Fling JA, Ruff ME, Parker WA, et al. Suppression of the late phase cutaneous response by immunotherapy. J Allergy Clin Immunol. 1989;83:101-109.
51. Parker WA Jr, Whisman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:667-677.
52. Freeman J. 'Rush' inoculation, with special reference to hay-fever treatment. Lancet. 1930;1:744-747.
53. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol. 1982;69:181-193.
54. Tipton WR, Nelson HS. Experience with daily immunotherapy in 59 adult allergic patients. J Allergy Clin Immunol. 1982;69:194-199.
55. Nataf P, Guinnepain MT, Herman D. Rush venom immunotherapy: a 3-day programme for hymenoptera sting allergy. Clin Allergy. 1984;14:269-275.
56. van der Zwan JC, Flinterman J, Jankowski IG, Kerckhaert JAM. Hyposensitisation to wasp venom in six hours. BMJ. 1983;287:1329-1331.
57. Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients. J Allergy Clin Immunol. 1989;84:951-959.
58. Thurnheer U, Müller U, Stoller R, Lanner A, Hoigne R. Venom immunotherapy in hymenoptera sting allergy: comparison of rush and conventional hyposensitization and observations during long-term treatment. Allergy. 1983;38:465-475.
59. Brown A. The perennial treatment of seasonal hay fever. J Allergy. 1932;3:113-119.
60. Fortner BR, Dantzler BS, Tipton WR, Nelson HS. The effect of weekly versus monthly ragweed allergen injections on immunological parameters. Ann Allergy. 1981;47:147-150.
61. Norman PS, Winkenwerder WL, Lichtenstein LM. Maintenance immunotherapy in ragweed hay fever. J Allergy. 1971;47:273-282.
62. Brown GT. Further experiences with maximum dosage pollen therapy. J Allergy. 1934;6:86-92.
63. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980;66:500-513.
64. Hirsch SR, Kalbfleisch JH, Golbert TM, et al. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol. 1981;63:133-155.
65. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardize, partially purified extract of house dust mite. J Allergy Clin Immunol. 1993;91:709-722.
66. Urbanek R, Forster J, Kuhn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr. 1985;107:367-371.
67. Golden DBK, Addison BI, Gadde J, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol. 1989;84: 162-167.
68. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995;96:879-885.
69. Ebner C, Kraft D, Ebner H. Booster immunotherapy. Allergy. 1994;49:38-42.
70. Vervloet D, Khairallah E, Arnaud A, Charpin J. A prospective national study of the safety of immunotherapy. Clin Allergy. 1980;10:59-64.
71. Lin MS, Tanner E, Lynn J, Friday GA. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993;71:557-562.
72. Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol. 1978;61:268-272.
73. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol. 1993;92:6-15.
74. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, IV: systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85:473-479.
75. Executive Committee, American Academy of Allergy and Immunology. Position statement: the waiting period after allergen skin testing and immunotherapy. J Allergy Clin Immunol. 1990;85:526-527.
76. Nelson HS. Long-term immunotherapy with aqueous and aluminum-precipitated grass extracts. Ann Allergy. 1980;40:333-337.
77. Lichtenstein LM, Norman PS, Winkenwerder WL. Antibody response following immunotherapy in ragweed hay fever. J Allergy. 1968;41:49-57.
78. Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy. 1985;15:179-193.
79. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1990;85:606-611.
80. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hayfever. J Allergy Clin Immunol. 1982;70:248-260.
81. Bousquet J, Hejjaoui A, Soussana M, Michel F-B. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, IV: comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol. 1990;85:490-497.
82. Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R. Safety and immunogenicity of immunotherapy with accelerated dosage schedules of polymerized grass and ragweed in patients with dual inhalant sensitivity. J Allergy Clin Immunol. 1989; 83:750-756.
83. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen. J Allergy Clin Immunol. 1984;73:484-489.
84. Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis, I: clinical response. J Allergy Clin Immunol. 1981;68:33-40.
85. Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis, II: immunologic response. J Allergy Clin Immunol. 1981; 68:41-45.
86. Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol. 1984;74:694-700.
87. Taudorf E, Weeke B. Orally administered grass pollen. Allergy. 1983;38:561-564.
88. Trede NS, Urbanek R. Combination of parenteral and oral immunotherapy in grass pollen-allergic children. Allergy. 1989;44:272-280.
89. Nelson HS, Oppenheimer J, Vatsia G, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1993;92:229-236.
90. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994;49:309-313.
91. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623-1628.